Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (REGN – Research Report), Aeglea Biotherapeutics (AGLE – Research Report) and Autolus Therapeutics (AUTL – Research Report).
Regeneron (REGN)
In a report released today, Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron, with a price target of $788.00. The company’s shares closed last Tuesday at $733.85, close to its 52-week high of $754.67.
According to TipRanks.com, Seigerman is a 4-star analyst with an average return of
Currently, the analyst consensus on Regeneron is a Moderate Buy with an average price target of $770.33, a 4.4% upside from current levels. In a report released yesterday, Goldman Sachs also maintained a Buy rating on the stock with a $970.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Aeglea Biotherapeutics (AGLE)
In a report released today, Edward White from H.C. Wainwright reiterated a Hold rating on Aeglea Biotherapeutics, with a price target of $1.00. The company’s shares closed last Tuesday at $0.53, close to its 52-week low of $0.37.
According to TipRanks.com, White has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Aeglea Biotherapeutics is a Hold with an average price target of $2.00.
Autolus Therapeutics (AUTL)
In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Autolus Therapeutics, with a price target of $18.00. The company’s shares closed last Tuesday at $2.58, close to its 52-week low of $1.96.
According to TipRanks.com, Goldstein is a 2-star analyst with an average return of
Autolus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $13.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on REGN:
